Cytodyn

CytoDyn Inc. is a clinical-stage biotechnology company based in Vancouver, Washington, specializing in the development of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infections. Its primary product candidate, PRO 140, is an entry inhibitor designed to block HIV from infecting cells and is currently undergoing various clinical trials, including Phase IIb and Phase IIb/III studies for HIV and trials for other conditions such as metastatic triple-negative breast cancer and graft-versus-host disease. The company also focuses on exploring additional therapeutic applications for PRO 140, targeting inflammatory conditions and autoimmune diseases. CytoDyn has established a strategic partnership with Samsung BioLogics for the clinical and commercial manufacturing of its therapies. Originally incorporated in 2002 under the name RexRay Corporation, CytoDyn aims to address significant health challenges associated with HIV and other immune-related disorders.